Sarepta Therapeutics Inc. has announced that the U.S. Food & Drug Administration (FDA) has granted platform technology designation to the rAAVrh74 viral vector used in their investigational gene therapy SRP-9003. This therapy targets limb-girdle muscular dystrophy type 2E/R4. The recognition is one of the first of its kind, highlighting the reproducibility and adaptability of the technology across multiple therapeutic programs. The designation is part of the FDA's initiative to enhance the efficiency of science-driven processes, aiding in the streamlined development, manufacturing, and review of drug applications. This move allows Sarepta to leverage existing data from the platform to support future drug applications, underscoring its commitment to advancing treatments for rare genetic diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.